This is an early-stage clinical update with no data yet. Traders should monitor for initial Phase 1 dose escalation data expected in 1H27, which will be the next meaningful catalyst for AN9025. The QW arm's potential to widen the therapeutic window is a positive differentiator but remains preclinical.
Price Chart
Executive Summary
Adlai Nortye announced the first patient dosed in the intermittent weekly (QW) dosing arm of the global Phase 1 trial for its pan-RAS(ON) inhibitor AN9025. This is a clinical milestone that expands the trial's dosing strategy, but it is an early-stage event with no data readout expected until the first half of 2027, making it a modest positive for the pipeline narrative rather than a material catalyst.
Key Facts
- First patient dosed in the intermittent weekly (QW) dosing arm of the Phase 1 trial for AN9025.
- Both the daily (QD) and weekly (QW) dose escalation arms are now enrolling.
- Initial Phase 1 dose escalation data from the QD arm is planned for 1H27, with a potential early look at the QW arm.
- AN9025 is an oral small molecule pan-RAS(ON) inhibitor targeting a broad spectrum of RAS mutations.
- The trial is a first-in-human, multicenter, open-label study in patients with advanced or metastatic solid tumors harboring RAS mutations.
Financial Impact
No financial data reported; this is a clinical milestone with no revenue or expense figures disclosed.
Risk Factors
- Phase 1 trial data may not support the differentiated weekly dosing hypothesis.
- No clinical data is available yet; the next data readout is not expected until 1H27.
- Competition in the pan-RAS inhibitor space is intense, with multiple programs advancing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-078874 |
| Document: ea0298278-6k_adlai.htm | 0001213900-26-078874 |
| Document: 0001213900-26-078874-index-headers.html | 0001213900-26-078874 |
| Document: 0001213900-26-078874-index.html | 0001213900-26-078874 |
| Document: 0001213900-26-078874.txt | 0001213900-26-078874 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.71 (−11.41%) |
Oct 15, 2026 12d ago | Press Release | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.71 (−11.41%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.71 (−33.06%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.71 (−33.06%) |
Sep 16, 2026 5w ago | EFFECT | $15.52 $15.75 | ▲ +1.48% | ▼ −0.34% | $10.71 (−30.99%) |
Aug 26, 2026 8w ago | 6-K | $15.06 $13.86 | ▼ −8.00% | ▼ −7.88% | $10.71 (−28.88%) |
Aug 19, 2026 9w ago | 6-K | $14.33 $15.06 | ▲ +5.09% | ▲ +5.48% | $10.71 (−25.26%) |
Aug 14, 2026 10w ago | 6-K | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.71 (−19.17%) |
Aug 14, 2026 10w ago | Press Release | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.71 (−19.17%) |
Aug 3, 2026 12w ago | 6-K | $12.99 $13.23 | ▲ +1.85% | ▼ −0.18% | $10.71 (−17.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers